Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Ongoing Initiated Nov 11, 2024 (2 years ago)

Docusate Sodium 250 mg

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

cGMP Deviations: Observations were made that some blister card-foils were separating from the blister cavity.

Cause type: Packaging defect

Failed child-resistant closures, leaks, cracked containers, or a defective delivery device. Packaging failures risk accidental exposure (especially to children) or product contamination. All packaging defect recalls.

What was recalled

Docusate Sodium 250 mg, 1 Softgel in blister card-foils, 100-count unit dose box, www.safecorhealth.com, NDC 48433-101-01

Affected NDC 48433-0101-01

Compare with the code on your package — it is the most precise check available.

Drug: Docusate

Recalling firm
Safecor Health, LLC
NDC code
48433-101-01
Origin
MA, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0060-2025 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall.

Other Docusate recalls

See all
Class II · Moderate risk

Docu Liquid

CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Ongoing Stability / shelf life Akorn, Inc. D-0801-2023

Other recalls by Safecor Health, LLC

All 2024 recalls